$0.52 -0.02 (%) Threshold Pharmaceuticals - NASDAQ

Jul. 27, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Threshold Pharmaceuticals Announces Workforce Reduction

    GuruFocus | Dec. 18, 2015 | 23:06PM EST
  2. Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not ...

    GuruFocus | Dec. 7, 2015 | 18:46PM EST
  3. Threshold Pharmaceuticals Announces Preclinical Data on Combination of Evofosfamide With Immune Checkpoint Inhibitors to Be Presented at the SITC 2015 Meeting

    Benzinga | Nov. 3, 2015 | 08:15AM EST
  4. Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide

    GuruFocus | Oct. 14, 2015 | 00:02AM EST
  5. Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide

    Benzinga | Oct. 13, 2015 | 07:02AM EST
  6. Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw Annual ...

    GuruFocus | Sep. 4, 2015 | 00:04AM EST
  7. Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) ...

    GuruFocus | Aug. 28, 2015 | 00:03AM EST
  8. Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib ...

    GuruFocus | Aug. 12, 2015 | 00:03AM EST
  9. Threshold Pharma, ATOMIC Initiate First Phase 2 Trial of TH-4000 in Patients with Advanced EGFR-Mutant, T790M-NSCLC

    Benzinga | Aug. 11, 2015 | 07:06AM EST
  10. Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald ...

    GuruFocus | Jul. 2, 2015 | 00:03AM EST
  11. Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL

    GuruFocus | May. 12, 2015 | 16:46PM EST
  12. Threshold Pharma Offers Preclinical Data Suggesting TH-4000 Could Overcome Resistance to Conventional EGFR Tyrosin Kinase Inhibitors

    Benzinga | Apr. 22, 2015 | 08:03AM EST
  13. Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) ...

    GuruFocus | Dec. 6, 2014 | 15:01PM EST
  14. Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in ...

    GuruFocus | Nov. 25, 2014 | 11:03AM EST
  15. Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus ...

    GuruFocus | Nov. 17, 2014 | 11:04AM EST
  16. Threshold Pharmaceuticals Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma

    Benzinga | Nov. 11, 2014 | 07:01AM EST
  17. Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare ...

    GuruFocus | Nov. 10, 2014 | 11:03AM EST
  18. Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be ...

    GuruFocus | Nov. 6, 2014 | 11:04AM EST
  19. Threshold Pharmaceuticals Announces New Phase 1/2 Data On TH-302 In Multiple Myeloma to Be Presented At The 2014 ASH Annual Meeting

    Benzinga | Nov. 6, 2014 | 09:06AM EST
  20. Threshold Pharma Says Phase 3 Trial of TH-302 in Patients with Advanced Soft Tissue Sarcoma Will Continue as Planned

    Benzinga | Sep. 22, 2014 | 08:04AM EST
  21. Events for the Week of Sept. 8-12

    Benzinga | Sep. 10, 2014 | 14:34PM EST
  22. Apple Unveils Watch, Larger iPhones; Francesca's Shares Drop After Downbeat Results

    Benzinga | Sep. 9, 2014 | 15:58PM EST
  23. Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation

    Benzinga | Sep. 5, 2014 | 09:43AM EST
  24. Threshold Announces Initiation Of Dosing With TH-302/Bortezomib In Final Stage Of Ongoing Phase 1/2 Trial Of Patients With Relapsed/Refractory Multiple Myeloma

    Benzinga | Jul. 9, 2014 | 07:01AM EST
  25. US Stock Futures Flat After Record Close

    Benzinga | Nov. 22, 2013 | 07:09AM EST
  26. Threshold Pharma Reports New Clinical Data on TH-302, Says One CR, Two Partial

    Benzinga | Nov. 22, 2013 | 07:06AM EST
  27. Threshold New Data on Combination of TH-302 and Avastin in Recurrent Glioblastoma to be Presented at WFNO/SNO

    Benzinga | Nov. 11, 2013 | 07:29AM EST
  28. Threshold Pharma Reports TH-302 Data Will Be Presented at ASH

    Benzinga | Nov. 7, 2013 | 09:01AM EST
  29. Threshold Pharma Reports Early Clinical Data for Combining TH-302, Says Trial Achieved Partial Response Rate 12%, Stable Disease Rate 64%

    Benzinga | Oct. 21, 2013 | 07:23AM EST
  30. Threshold Pharmaceuticals Initiates Phase 2 Study of TH-302 in Patients With Advanced Melanoma

    Benzinga | Aug. 8, 2013 | 07:09AM EST
  31. UPDATE: Piper Jaffray Initiates Threshold Pharmaceuticals at Neutral Ahead of Pivotal Data

    Benzinga | Jan. 18, 2013 | 01:08AM EST
  32. Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 2, 2012 | 13:08PM EST
  33. Threshold Pharmaceuticals Announces Agreement With U.S. FDA on a Special Protocol Assessment for Planned Phase 3 Trial of TH-302

    Benzinga | Oct. 16, 2012 | 01:35AM EST
  34. Maxim Group Reiterates Buy Rating, $10 PT on Threshold Pharmaceuticals

    Benzinga | Oct. 1, 2012 | 06:21AM EST
  35. UPDATE: Maxim Group Initiates Threshold Pharmaceuticals at Buy on Doxorubicin Potential

    Benzinga | Sep. 20, 2012 | 07:35AM EST
  36. Threshold Pharmaceuticals (THLD) Loses 20.5% on Mixed Data from Drug Trial

    MarketIntelligenceCenter | Sep. 17, 2012 | 12:54PM EST
  37. Morning Market Losers

    Benzinga | Sep. 17, 2012 | 03:56AM EST
  38. FROM EARLIER: Threshold Pharma Says Study of TH-302 Demonstrated a Statistically Significant 63% Improvement in Patients

    Benzinga | Sep. 17, 2012 | 03:31AM EST
  39. Eli Lilly &, Limited Brands Included in Stocks Up on High Volume Friday

    FoxBusiness | Aug. 24, 2012 | 06:33AM EST
  40. Threshold Pharmaceuticals Appoints Laura G. Hansen, Ph.D., Senior Director, Corporate Communications

    Benzinga | Aug. 16, 2012 | 01:30AM EST
  41. Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 6, 2012 | 03:19AM EST
  42. Benzinga's Top Initiations

    Benzinga | Jul. 10, 2012 | 01:28AM EST
  43. Bullish Brokerage Note Propels Threshold Pharmaceuticals' Call Volume

    SchaeffersResearch | Apr. 3, 2012 | 10:33AM EST
  44. Threshold Pharma Pops 18% on Positive Quarterly Results

    Benzinga | Mar. 8, 2012 | 03:14AM EST
  45. Nine ETFs Trading Near 52-Week Highs

    Benzinga | Mar. 4, 2012 | 06:11AM EST
  46. These Small-Cap Stocks Have Already More Than Doubled In 2012!

    Benzinga | Feb. 23, 2012 | 08:47AM EST
  47. Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer

    Benzinga | Feb. 21, 2012 | 00:14AM EST
  48. Benzinga's Microcap Movers for Friday February 3, 2012

    Benzinga | Feb. 5, 2012 | 04:39AM EST
  49. Financial Breakfast: Morning News Summary for February 3, 2012

    Benzinga | Feb. 3, 2012 | 00:21AM EST
  50. Threshold Pharmaceuticals Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias

    Benzinga | Dec. 13, 2011 | 23:51PM EST
Trading Center